7:26 AM
Apr 06, 2018
 |  BC Extra  |  Clinical News

Incyte tumbles after epacadostat miss

Editor's Note: This article was updated on Apr 06, 2018 at 11:54 AM PDT

Incyte Corp. (NASDAQ:INCY) fell $19.05 (23%) to $64.02 on Friday after the company and partner Merck & Co. Inc. (NYSE:MRK) said epacadostat plus Merck’s anti-PD-1 mAb Keytruda pembrolizumab missed the primary endpoint in the Phase III ECHO-301/KEYNOTE-252 trial as first-line treatment of unresectable or metastatic melanoma. The move translates to a loss in Incyte's market cap of about $4 billion.

Incyte's epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor (see BioCentury, June 16, 2017).

The partners said the trial will be stopped after a DMC review showed that the combo missed the primary endpoint of improving progression-free survival (PFS) vs. Keytruda alone (HR=1). The partners said the second primary endpoint...

Read the full 534 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >